Skip to content
Operation Infinite Justice – Lifestyle
Author:
NOVO NORDISK INC.
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
July 21, 2026
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
July 11, 2026
No easy answers: European research consortia take on major challenges
July 10, 2026
Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge
July 1, 2026
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
June 26, 2026
New European initiative to accelerate drug discovery for cardiometabolic diseases
June 19, 2026
Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
June 7, 2026
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
June 7, 2026
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions
June 6, 2026
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
June 6, 2026
1
2
Next Page
→